Pulmonary Fibrosis

For individuals related to someone with familial interstitial pneumonia, the prevalence of pulmonary fibrosis was around 1,000 per 100,000 person-years, according to study results.

WASHINGTON — In patients with idiopathic pulmonary fibrosis, yearly lung function decline rates did not improve with two different dosages of ziritaxestat, according to an American Thoracic Society International Conference presentation.

Thirty-nine percent of patients who suffered a COVID-19 infection had interstitial lung abnormalities 2 years following the illness, according to study results published in Radiology.

Black patients with pulmonary fibrosis are younger at diagnosis and death than Hispanic and white patients with pulmonary fibrosis, according to study results published in JAMA Network Open.

Almost 90% of Americans are unaware of the symptoms that signal pulmonary fibrosis due to the disease’s rarity, according to a Pulmonary Fibrosis Foundation survey.

About half of patients with interstitial lung abnormalities had suspected interstitial lung disease, with these patients having greater symptoms and more unfavorable clinical outcomes, according to study results.

The FDA granted orphan drug designation to INS018_055, an anti-fibrotic small molecule inhibitor, for treating patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Patients with systemic sclerosis who report more severe reflux symptoms demonstrate worse interstitial lung disease outcomes despite receiving standard therapy, according to data published in Arthritis Care & Research.

Compared with high-resolution CT, chest radiography appeared less accurate in detecting interstitial lung disease, according to a study published in Annals of the American Thoracic Society.